Rudhir Tandon, MD
Interventional Cardiology · Fort Smith, ARNPI 1245486547
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $15,165 of the $21,523 with a category attached, or 70.5%. 27 manufacturers reported payments, led by Abbott at 38.6% of the total. Reporting peaked in 2019 at $12,034 and has fallen 98.7% since, to $152 in 2025.
Across 205 payments — averaging $104.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$8K
- Medtronic$4K
- Boston Scientific$3K
- Edwards Lifesciences$1K
- Penumbra, Inc.$1K
- Philips North America LLC$1K
- plus $2K from 21 others
What the payments were for
- Consulting fees$1551%
- Grants$1721%
- Travel & lodging$15,16570%
- Food & beverage$5,98928%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 58 | $8,310 |
| Medtronic(2 entities) | 31 | $4,440 |
| Boston Scientific | 32 | $3,375 |
| Edwards Lifesciences | 12 | $1,433 |
| Penumbra, Inc. | 3 | $1,283 |
| Philips North America LLC | 2 | $1,147 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $207 |
| Abiomed | 10 | $194 |
| Cook Medical LLC | 1 | $172 |
| Inari Medical, Inc. | 2 | $146 |
| Cardiovascular Systems Inc. | 1 | $101 |
| Cardinal Health 200 LLC | 2 | $92 |
| Amgen | 5 | $87 |
| Novo Nordisk | 4 | $83 |
| Johnson & Johnson | 4 | $67 |
| Irhythm Technologies, Inc. | 3 | $56 |
| Novartis | 3 | $56 |
| Pfizer | 4 | $54 |
| AstraZeneca | 3 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Angiodynamics, Inc. | 1 | $23 |
| Baxter Healthcare | 1 | $18 |
| Merck | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnilink Elite vascular stent system$3,191
- OMNILINK ELITE$2,050
- Indigo$1,216
- CoreValve Evolut$1,207
- Xience V coronary stent system$1,174
- Micra$1,158
- IGT D Peripheral$1,147
- ROTABLATOR$1,068
- VenaSeal$909
- Watchman$774
- GENERAL - THERAPIES$599
- FLOWTRIEVER CATHETER, S$267
- SUPERA$157
- GENERAL BRADY$139
- Coronary Orbital Atherectomy System$101
How this compares
$21,523 in reported general payments places this provider in the 85th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 243 | $221,366 |
| EntrestoSacubitril/Valsartan | 56 | $61,531 |
| XareltoRivaroxaban | 55 | $45,291 |
| BrilintaTicagrelor | 37 | $42,797 |
| JardianceEmpagliflozin | 36 | $38,870 |
| Ranolazine ErRanolazine | 144 | $8,756 |
| Metoprolol Succinate | 597 | $6,389 |
| Bumetanide | 118 | $3,797 |
| Atorvastatin Calcium | 479 | $3,626 |
| Carvedilol | 337 | $2,392 |
| ClopidogrelClopidogrel Bisulfate | 208 | $2,108 |
| Losartan Potassium | 215 | $1,541 |
| Furosemide | 330 | $1,509 |
| Pantoprazole Sodium | 123 | $1,435 |
| Amlodipine Besylate | 247 | $1,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $54 | $221,366243 claims |
| NovartisEntresto | $56 | $61,53156 claims |
| Johnson & JohnsonXarelto | $67 | $45,29155 claims |
| AstraZenecaBrilinta | $43 | $42,79737 claims |
| Boehringer IngelheimJardiance | $13 | $38,87036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Fort Smith
- Hussam HawamdehFort Smith$16K
- Pooja MishraFort Smith$10K
- Jose Loyo MolinaFort Smith$9K
- Gaurav DharLittle Rock$206K
- Ernesto Ruiz-RodriguezLittle Rock$153K
- Vasili LendelLittle Rock$86K
- Thomas WattsLittle Rock$68K
- Vijay RajaLittle Rock$46K
- Lena AwarJonesboro$43K
- Zubair AhmedFayetteville$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.